EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia

Hsiao-Jen Chung iD, Chihiro Kondoh, Woo Kyun Bae, Satoshi Tamada, Nobuaki Matsubara iD, Hyo Jin Lee, Ryuichi Mizuno, Satoshi Anai, Go Kimura, Yoshihiko Tomita iD, Chao-Hsiang Chang, John Wen-Cheng Chang und 6 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae182 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hsiao-Jen Chung und 17 weiteren Autor:innen. Beteiligte Einrichtung: Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sunitinib, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The phase 3 open-label KEYNOTE-426 study demonstrated that first-line pembrolizumab plus axitinib improved overall survival (OS) and progression-free survival (PFS) versus sunitinib for metastatic renal cell carcinoma (mRCC) in a global population. This subgroup analysis investigated the efficacy and safety of pembrolizumab-axitinib versus sunitinib in patients enrolled in KEYNOTE-426 in East Asia (Japan, South Korea, and Taiwan).

Methods

Adults with clear cell mRCC were randomly assigned 1:1 to receive intravenous pembrolizumab 200 mg every 3 weeks with oral axitinib 5 mg twice daily or oral sunitinib 50 mg once daily (4 weeks on/2 weeks off). Dual primary endpoints were OS and PFS, assessed by blinded independent central review. Secondary endpoints were objective response rate (ORR) and safety.

Results

The East Asian subgroup comprised 130 patients (pembrolizumab-axitinib, n = 62; sunitinib, n = 68; 15.1% of the global intention-to-treat population). Compared with sunitinib, pembrolizumab-axitinib OS hazard ratio (HR) was 0.85 [95% confidence interval (CI) 0.50–1.44; 36-month rates, 62.9% and 58.8%, respectively] and PFS HR was 0.59 (95% CI 0.38–0.92) in favor of pembrolizumab-axitinib. ORR favored pembrolizumab-axitinib (64.5% vs 44.1% for sunitinib). The results were generally consistent with the intention-to-treat population. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 69.4% of patients on pembrolizumab-axitinib and 74.6% on sunitinib; 16 (25.8%) patients on pembrolizumab-axitinib and 17 (25.4%) patients on sunitinib discontinued due to adverse events. No deaths from TRAEs occurred.

Conclusion

Pembrolizumab-axitinib improved efficacy for East Asian patients with untreated clear cell mRCC, consistent with results from the global population. Safety was manageable. ClinicalTrials.gov identifier: NCT02853331.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSunitinibCarcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAxitinibAdultProgression-Free SurvivalAsia, EasternAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

PD-1 checkpoint inhibitoraxitinibmetastatic renal cell carcinomapembrolizumabvascular endothelial growth factor receptor inhibitor

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedSunitinibAxitinib

Autor:innen und Institutionen

  • Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, Taiwan.
  • College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Daxue rd, East District, Taipei, 30010, Taiwan.
  • Toranomon Hospital, 2 Chome-2-2 Toranomon, Minato City, Tokyo 105-8470, Japan.
  • Chonnam National University Hospital and College of Medicine, Gwangju, Dong-gu, Baekseo-ro, 160, Hwasun, Republic of Korea.
  • Osaka Metropolitan University, 599-8247 Higashiyama 500-3 Naka-ku, Sakai City, Osaka, Japan.
  • National Cancer Center Hospital East, $\overline\top$277-8577 Chiba, Kashiwa, Kashiwanoha, 6 Chome-5-1, Japan.

ORCID-Profile: Hsiao-Jen Chung, Nobuaki Matsubara, Yoshihiko Tomita, Hirotsugu Uemura

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Chung, H. J., Kondoh, C., Bae, W. K., Tamada, S., Matsubara, N., Lee, H. J., Mizuno, R., Anai, S., Kimura, G., Tomita, Y., Chang, C. H., Chang, J. W., Lin, J., Perini, R. F., Molife, L. R., Powles, T., Rini, B. I., & Uemura, H. (2025). First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae182

Vancouver

Chung HJ, Kondoh C, Bae WK, Tamada S, Matsubara N, Lee HJ, et al. First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae182

BibTeX
@article{Chung2025,
  author = {Chung, Hsiao-Jen and Kondoh, Chihiro and Bae, Woo Kyun and Tamada, Satoshi and Matsubara, Nobuaki and Lee, Hyo Jin and Mizuno, Ryuichi and Anai, Satoshi and Kimura, Go and Tomita, Yoshihiko and Chang, Chao-Hsiang and Chang, John Wen-Cheng and Lin, Jianxin and Perini, Rodolfo F and Molife, L Rhoda and Powles, Thomas and Rini, Brian I and Uemura, Hirotsugu},
  title = {First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae182}
}
Kostenlos starten →